Karlsson Per, Cole Bernard F, Price Karen N, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Castiglione Monica, Colleoni Marco, Gruber Günther
Department of Oncology, Institute of Clinical Sciences, Sahgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Mathematics and Statistics, University of Vermont, Burlington, Vermont.
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):273-279. doi: 10.1016/j.ijrobp.2016.06.2448.
To update the previous report from 2 randomized clinical trials, now with a median follow-up of 16 years, to analyze the effect of radiation therapy timing on local failure and disease-free survival.
From July 1986 to April 1993, International Breast Cancer Study Group trial VI randomly assigned 1475 pre-/perimenopausal women with node-positive breast cancer to receive 3 or 6 cycles of initial chemotherapy (CT). International Breast Cancer Study Group trial VII randomly assigned 1212 postmenopausal women with node-positive breast cancer to receive tamoxifen for 5 years, or tamoxifen for 5 years with 3 early cycles of initial CT. For patients who received breast-conserving surgery (BCS), radiation therapy (RT) was delayed until initial CT was completed; 4 or 7 months after BCS for trial VI and 2 or 4 months for trial VII. We compared RT timing groups among 433 patients on trial VI and 285 patients on trial VII who received BCS plus RT. Endpoints were local failure, regional/distant failure, and disease-free survival (DFS).
Among pre-/perimenopausal patients there were no significant differences in disease-related outcomes. The 15-year DFS was 48.2% in the group allocated 3 months initial CT and 44.9% in the group allocated 6 months initial CT (hazard ratio [HR] 1.12; 95% confidence interval [CI] 0.87-1.45). Among postmenopausal patients, the 15-year DFS was 46.1% in the no-initial-CT group and 43.3% in the group allocated 3 months initial CT (HR 1.11; 95% CI 0.82-1.51). Corresponding HRs for local failures were 0.94 (95% CI 0.61-1.46) in trial VI and 1.51 (95% CI 0.77-2.97) in trial VII. For regional/distant failures, the respective HRs were 1.15 (95% CI 0.80-1.63) and 1.08 (95% CI 0.69-1.68).
This study confirms that, after more than 15 years of follow-up, it is reasonable to delay radiation therapy until after the completion of standard CT.
更新之前来自2项随机临床试验的报告,目前中位随访时间为16年,以分析放疗时机对局部复发和无病生存期的影响。
1986年7月至1993年4月,国际乳腺癌研究组试验VI将1475例绝经前/围绝经期淋巴结阳性乳腺癌女性随机分配接受3或6周期的初始化疗(CT)。国际乳腺癌研究组试验VII将1212例绝经后淋巴结阳性乳腺癌女性随机分配接受5年他莫昔芬治疗,或5年他莫昔芬治疗加3周期初始CT。对于接受保乳手术(BCS)的患者,放疗(RT)推迟至初始CT完成后进行;试验VI在BCS后4或7个月进行,试验VII在BCS后2或4个月进行。我们比较了试验VI中433例和试验VII中285例接受BCS加RT患者的放疗时机组。终点指标为局部复发、区域/远处复发和无病生存期(DFS)。
在绝经前/围绝经期患者中,疾病相关结局无显著差异。初始CT为3个月组的15年DFS为48.2%,初始CT为6个月组的15年DFS为44.9%(风险比[HR]1.12;95%置信区间[CI]0.87 - 1.45)。在绝经后患者中,无初始CT组的15年DFS为46.1%,初始CT为3个月组的15年DFS为43.3%(HR = 1.11;95% CI 0.82 - 1.51))。试验VI中局部复发的相应HR为0.94(95% CI 0.